Cargando…

Global Prevalence and Associated Clinical Markers of Thrombocytopenia in People Living with HIV: Evidence from Meta-Analysis

Thrombocytopenia is one of the complications in human immunodeficiency virus (HIV) patients. To improve the health outcomes of patients living with HIV, it is important to understand the prevalence and pattern of associated key clinical markers globally. This meta-analysis, therefore, aimed to estim...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkholifi, Faisal K., Abdi, Sayed Aliul Hasan, Qadri, Marwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680325/
https://www.ncbi.nlm.nih.gov/pubmed/36412670
http://dx.doi.org/10.3390/clinpract12060091
_version_ 1784834390482747392
author Alkholifi, Faisal K.
Abdi, Sayed Aliul Hasan
Qadri, Marwa
author_facet Alkholifi, Faisal K.
Abdi, Sayed Aliul Hasan
Qadri, Marwa
author_sort Alkholifi, Faisal K.
collection PubMed
description Thrombocytopenia is one of the complications in human immunodeficiency virus (HIV) patients. To improve the health outcomes of patients living with HIV, it is important to understand the prevalence and pattern of associated key clinical markers globally. This meta-analysis, therefore, aimed to estimate the pooled prevalence of and associated clinical marker of thrombocytopenia globally. Methodology: The meta-analysis was conducted as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. All statistical analyses were conducted using Stata. Twelve full-text papers out of 454 were eligible for meta-analysis. Results: Among 6686 participants, overall pooled prevalence of thrombocytopenia was 10.90% (95% CI: 7.91, 13.88) I(2) = 93.62%. In addition, thrombocytopenia was more prevalent by 25.11% (95% CI: 13.33, 36.88) in patients with CD + T < 200 cells/μL, and less prevalent in patients with CD + T < 200 cells/μL 10.10% (95% CI: 7.37, 12.83), respectively. Conclusions and recommendations: This meta-analysis established the prevalence of thrombocytopenia among patients living with HIV, and that it may be more prevalent in patients with CD + T < 200 cells/μL indicating the necessity of routine screening for various haematological markers and a careful treatment plan for HIV patients.
format Online
Article
Text
id pubmed-9680325
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96803252022-11-23 Global Prevalence and Associated Clinical Markers of Thrombocytopenia in People Living with HIV: Evidence from Meta-Analysis Alkholifi, Faisal K. Abdi, Sayed Aliul Hasan Qadri, Marwa Clin Pract Article Thrombocytopenia is one of the complications in human immunodeficiency virus (HIV) patients. To improve the health outcomes of patients living with HIV, it is important to understand the prevalence and pattern of associated key clinical markers globally. This meta-analysis, therefore, aimed to estimate the pooled prevalence of and associated clinical marker of thrombocytopenia globally. Methodology: The meta-analysis was conducted as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. All statistical analyses were conducted using Stata. Twelve full-text papers out of 454 were eligible for meta-analysis. Results: Among 6686 participants, overall pooled prevalence of thrombocytopenia was 10.90% (95% CI: 7.91, 13.88) I(2) = 93.62%. In addition, thrombocytopenia was more prevalent by 25.11% (95% CI: 13.33, 36.88) in patients with CD + T < 200 cells/μL, and less prevalent in patients with CD + T < 200 cells/μL 10.10% (95% CI: 7.37, 12.83), respectively. Conclusions and recommendations: This meta-analysis established the prevalence of thrombocytopenia among patients living with HIV, and that it may be more prevalent in patients with CD + T < 200 cells/μL indicating the necessity of routine screening for various haematological markers and a careful treatment plan for HIV patients. MDPI 2022-10-31 /pmc/articles/PMC9680325/ /pubmed/36412670 http://dx.doi.org/10.3390/clinpract12060091 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alkholifi, Faisal K.
Abdi, Sayed Aliul Hasan
Qadri, Marwa
Global Prevalence and Associated Clinical Markers of Thrombocytopenia in People Living with HIV: Evidence from Meta-Analysis
title Global Prevalence and Associated Clinical Markers of Thrombocytopenia in People Living with HIV: Evidence from Meta-Analysis
title_full Global Prevalence and Associated Clinical Markers of Thrombocytopenia in People Living with HIV: Evidence from Meta-Analysis
title_fullStr Global Prevalence and Associated Clinical Markers of Thrombocytopenia in People Living with HIV: Evidence from Meta-Analysis
title_full_unstemmed Global Prevalence and Associated Clinical Markers of Thrombocytopenia in People Living with HIV: Evidence from Meta-Analysis
title_short Global Prevalence and Associated Clinical Markers of Thrombocytopenia in People Living with HIV: Evidence from Meta-Analysis
title_sort global prevalence and associated clinical markers of thrombocytopenia in people living with hiv: evidence from meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680325/
https://www.ncbi.nlm.nih.gov/pubmed/36412670
http://dx.doi.org/10.3390/clinpract12060091
work_keys_str_mv AT alkholififaisalk globalprevalenceandassociatedclinicalmarkersofthrombocytopeniainpeoplelivingwithhivevidencefrommetaanalysis
AT abdisayedaliulhasan globalprevalenceandassociatedclinicalmarkersofthrombocytopeniainpeoplelivingwithhivevidencefrommetaanalysis
AT qadrimarwa globalprevalenceandassociatedclinicalmarkersofthrombocytopeniainpeoplelivingwithhivevidencefrommetaanalysis